Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

uriel pharmacy inc. - arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), astragalus propinquus root (unii: 922op8yupf) (astragalus propinquus root - unii:922op8yupf), formica rufa (unii: 55h0w83jo5) (formica rufa - unii:55h0w83jo5), silver (unii: 3m4g523w1g) (silver - unii:3m4g523w1g) - arnica montana 3 [hp_x] in 1 ml - directions: for oral use. use: temporary relief of headache.

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - hepatitis b immunoglobulin - solution for injection - hepatitis b immunoglobulin 312 iu/ml - hepatitis b immunoglobulin - hepatitis b immunoglobulin - prevention of hepatitis b recurrence following liver transplantation : hepagam b is indicated for the prevetion of hepatitis b recurrence following liver transplantation in hbsag-positive liver transplant patients. hepagam b should be administered intravenously for this indication.postexposure prophylaxis : hepagam b is indicated for the treatment of acute exposure to blood containing hbsag perinatal exposure of infants born to hbsag-positive mothers sexual exposure to hbsag-positive persons and household exposure to persons with acute hbv infection in the following settings: acute exposure to blood containing hbsag following either parenteral exposure (needlestick bite sharps) direct mucous membrane contact (accidental splash) or oral ingestion (pipetting accident) involving hbsag - positive materials such as blood plasma or serum. perinatal exposure of infants born to hbsag-positive mothers infants born to mothers positive for hbsag with or without hbeag. perinatal exposure of infants born to hbsag-positive persons sexual partners of hbsag-positive persons. household exposure to persons with acute hbv infection infants less than 12 months old whose mother or primary caregiver is positive for hbsag. other household contacts with an identifiable blood exposure to the index patient. hepagam b is indicated for intramuscular use only for these post-exposure prophylaxis indications.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

aptevo biotherapeutics llc - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - human hepatitis b virus immune globulin 312 [iu] in 1 ml - hepagam b [hepatitis b immune globulin intravenous (human)] is an intravenous immune globulin indicated for the following: including - acute exposure to hbsag-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc), - perinatal exposure of infants born to hbsag-positive mothers, - sexual exposure to hbsag-positive persons, and - household exposure to persons with acute hbv infection. - individuals known to have anaphylactic or severe systemic reactions to the parenteral administration of human globulin preparations should not receive hepagam b. - individuals who are deficient in iga may have the potential to develop anti-iga antibodies and have an anaphylactoid reaction. hepagam b contains less than 40 micrograms per milliliter of iga. - hepagam b contains less than 40 micrograms per milliliter of iga. - for postexposure prophylaxis indications, hepagam b must be administered intramuscularly only. in patients who have severe thrombocytopenia or any coagulat

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

aptevo biotherapeutics llc - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - hepagam b [hepatitis b immune globulin intravenous (human)] is an intravenous immune globulin indicated for the following: including - acute exposure to hbsag-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc), - perinatal exposure of infants born to hbsag-positive mothers, - sexual exposure to hbsag-positive persons, and - household exposure to persons with acute hbv infection. - individuals known to have anaphylactic or severe systemic reactions to the parenteral administration of human globulin preparations should not receive hepagam b. - individuals who are deficient in iga may have the potential to develop anti-iga antibodies and have an anaphylactoid reaction. hepagam b contains less than 40 micrograms per milliliter of iga. - hepagam b contains less than 40 micrograms per milliliter of iga. - for postexposure prophylaxis indications, hepagam b must be administered intramuscularly only. in patients who have severe thrombocytopenia or any coagulat

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

saol therapeutics inc. - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - hepagam b [hepatitis b immune globulin intravenous (human)] is an intravenous immune globulin indicated for the following: including - acute exposure to hbsag-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc.), - perinatal exposure of infants born to hbsag-positive mothers, - sexual exposure to hbsag-positive persons, and - household exposure to persons with acute hbv infection. - individuals known to have anaphylactic or severe systemic reactions to the parenteral administration of human globulin preparations should not receive hepagam b. - individuals who are deficient in iga may have the potential to develop anti-iga antibodies and have an anaphylactoid reaction. hepagam b contains less than 40 micrograms per milliliter of iga. - hepagam b contains less than 40 micrograms per milliliter of iga. - for postexposure prophylaxis indications, hepagam b must be administered intramuscularly only. in patients who have severe thrombocytopenia or any coagulat

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

saol therapeutics inc. - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - hepagam b [hepatitis b immune globulin intravenous (human)] is an intravenous or intramuscular immune globulin indicated for the following: including - acute exposure to hbsag-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc.), - perinatal exposure of infants born to hbsag-positive mothers, - sexual exposure to hbsag-positive persons, and - household exposure to persons with acute hbv infection. - individuals known to have anaphylactic or severe systemic reactions to the parenteral administration of human globulin preparations should not receive hepagam b. - individuals who are deficient in iga may have the potential to develop anti-iga antibodies and have an anaphylactoid reaction. hepagam b contains less than 40 micrograms per milliliter of iga. - hepagam b contains less than 40 micrograms per milliliter of iga. - for postexposure prophylaxis indications, hepagam b must be administered intramuscularly only. in patients who have severe thrombocytopeni

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

kamada ltd. - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - hepagam b [hepatitis b immune globulin intravenous (human)] is an intravenous immune globulin indicated for the following: including - acute exposure to hbsag-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc.), - perinatal exposure of infants born to hbsag-positive mothers, - sexual exposure to hbsag-positive persons, and - household exposure to persons with acute hbv infection. - individuals known to have anaphylactic or severe systemic reactions to the parenteral administration of human globulin preparations should not receive hepagam b. - individuals who are deficient in iga may have the potential to develop anti-iga antibodies and have an anaphylactoid reaction. hepagam b contains less than 40 micrograms per milliliter of iga. - hepagam b contains less than 40 micrograms per milliliter of iga. - for postexposure prophylaxis indications, hepagam b must be administered intramuscularly only. in patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, hepagam b should be given only if the expected benefits outweigh the potential risks. pregnancy category c. animal reproduction studies have not been conducted with hepagam b. it is also not known whether hepagam b can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. hepagam b should be given to a pregnant woman only if clearly indicated. it is not known whether hepagam b is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when hepagam b is administered to a nursing mother. safety and effectiveness have not been established in pediatric patients. however, for postexposure prophylaxis, the safety and effectiveness of similar hepatitis b immune globulins have been demonstrated in infants and children 8 . clinical studies of hepagam b did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

great grand care pty ltd - glycyrrhiza glabra, quantity: 89.3 mg/g; zingiber officinale, quantity: 44.7 mg/g; stephania tetranda, quantity: 178.7 mg/g; atractylodes macrocephala, quantity: 134 mg/g; astragalus membranaceus, quantity: 178.7 mg/g; ziziphus jujuba, quantity: 44.7 mg/g - granules - excipient ingredients: potato starch - traditionally used in chinese medicine to promote water metabolism ; traditionally used in chinese medicine to dissipate retained-fluid/water ; traditionally used in chinese medicine to increase/augment/generate/promote/strengthen qi ; traditionally used in chinese medicine to tonify/nourish/strengthen/replenish/fortify/invigorate spleen

Australija - engleski - Department of Health (Therapeutic Goods Administration)

great grand care pty ltd - zingiber officinale, quantity: 89.2 mg/g; astragalus membranaceus, quantity: 178.5 mg/g; cinnamomum cassia, quantity: 89.2 mg/g (equivalent: coumarin, qty 0.0004 mg/g); ziziphus jujuba, quantity: 53.5 mg/g; paeonia lactiflora, quantity: 89.2 mg/g - granules - excipient ingredients: potato starch - traditionally used in chinese medicine to increase/augment/generate/promote/strengthen qi ; traditionally used in chinese medicine to enhance generation/transformation of nutritive-qi ; traditionally used in chinese medicine to increase/augment protective-qi/wei-qi

Australija - engleski - Department of Health (Therapeutic Goods Administration)

global therapeutics pty ltd - astragalus membranaceus,atractylodes macrocephala,codonopsis pilosula,eleutherococcus senticosus,ganoderma lucidum,glycyrrhiza uralensis,ligustrum lucidum,schisandra chinensis -